Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...
Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease ...
Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.
In September 2024, Cidara initiated a randomized, double-blind, controlled Phase 2b trial targeting enrollment of 5,000 ...
Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...
How do you stop implicit bias from getting in the way of better health? This doctor wants to make learning how to manage bias as important as learning how to suture. Hurricane Milton Delays Launch ...
Scientific community and society encompasses research and material which directly concerns, or is relevant to, members of the community of scientists in particular or society at large. A mixed ...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...
These can be used to provide you with additional information that is relevant to your work or scientific areas of interest ... or otherwise use such information in any format, and there is no ...
Nov. 5, 2024 — New research from reveals that the gut microbiome regulates the body's diurnal (day-night) rhythms in stress hormones. Depletion of gut microbiota ... Not the Usual Suspects ...
Hanmi presented two preclinical studies in poster format, underscoring HM17321’s double-action(fat loss and lean muscle gain) benefits and a development strategy that highlights both quantitative and ...